Pricing Log in Create free account
Friday 6 November 2026 Export UFPT’s income statement to Excel — free account

UFP Technologies, Inc.

UFPT Healthcare Medical Devices

UFP Technologies, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $602.8 million, up 19.5% from fiscal 2024.

Revenue
+11.6%
EPS
+25.6%
Free cash flow
−35.8%
Total debt
−40.2%

Quarter to September 2026, against a year earlier

302.15 2.33 +0.78%
Market cap
$2.3B
P/E
30.1×
Fwd P/E
29.2×
Dividend yield
—
F-score
5/9
Altman Z
6.86
Beneish M
−2.57
Dividend safety
n/a
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Insider Decisions last twelve months

Sold, $m 13.58
Trades a month
Jan 26 Apr 26 Jul 26 Oct 26
Buy — — — — — — — — — — — —
Sell 1 — — — — 1 1 — 7 — — —
Insider Ownership 3.82%

Capital & Financial Ratios $m

Size
Market Cap 2,320.00
Revenue ttm 649.52
Net income ttm 72.30
Free cash flow ttm 61.50
Net debt Q 75.38
Valuation
P/E 30.06
Forward P/E 29.20
Price / sales 3.55
Forward P/S Powerpack
Price / FCF 37.49
Price / book 4.99
Financial health
Current ratio Q 2.98 (at or above 1.5: strong)
Debt / equity Q 0.20 (at or below 0.5: strong)
Interest coverage Q 18.50
Growth
Revenue growth Q +11.57% (above 0%: growing)
Operating income growth Q +18.08% (above 0%: growing)
EPS, this year +11.91%
EPS, next year A +11.41%
Revenue, next year A +9.12%
EPS, past 5 yrs +37.66% (at or above 15%: strong)
EPS, next 5 yrs A +14.49%

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 3.7×, against a ten-year median of 2.1×; over the ten years it ranged from 0.9× in 2016 to 6.3× in 2024.
P/E against its own 10 years 78.69%
10-year low 10-year high
P/S against its own 10 years 88.08%
10-year low 10-year high
P/B against its own 10 years 86.21%
10-year low 10-year high
EV/Sales against its own 10 years 87.17%
10-year low 10-year high
EV/FCF against its own 10 years 64.69%
10-year low 10-year high

Dividends

Yield
—
Annual rate
—
Payout ratio
—

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 5 13 20 21
Receivables 66 90 88 97
Inventory 70 88 87 98
Other — — — 15
145 195 201 231
2023 2024 2025 Q'26
Payables 22 24 24 26
ST’ Debt 4 13 13 13
Other — — — 38
58 76 75 77

Compound Annual Growth %

10y 5y 3y
Sales 15.81% 27.43% 19.44%
Cash Flow 22.06% 29.70% 73.02%
Earnings 24.57% 38.57% 17.80%
Book Value 15.13% 19.10% 21.29%

Earnings Trends EPS, adjusted, against the consensus

Q3 FY26 Estimate 2.63 Actual 2.88

Earnings per share against the consensus, by quarter
Quarter Estimate Reported Result
Q4 FY25 2.26 2.44 Beat by 0.18
Q1 FY26 2.18 2.48 Beat by 0.30
Q2 FY26 2.51 2.92 Beat by 0.41
Q3 FY26 2.63 2.88 Beat by 0.25
Q4 FY26 2.52 — Reports 23 February 2027

EPS $

Mar Jun Sep Dec Year
’26 2.24 2.68 2.64 — —
’25 2.21 2.21 2.11 2.25 8.75
’24 1.64 1.75 2.11 2.10 7.58
’23 1.27 1.55 1.52 1.51 5.83
’22 0.64 1.17 2.56 1.10 5.45
’21 0.55 0.62 0.50 0.42 2.09
’20 0.52 0.31 0.40 0.55 1.77
Fiscal quarters ending in the months shown.

Revenue $m

Mar Jun Sep Dec Year
’26 154 174 172 — —
’25 148 151 155 149 603
’24 105 110 145 144 504
’23 98 100 101 101 400
’22 71 94 97 91 354
’21 49 51 51 56 206
’20 48 43 43 45 179
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 3 16 — — —
’25 14 25 36 17 92
’24 11 12 20 24 67
’23 2 9 18 13 41
’22 (3) 3 0 18 18
’21 3 7 4 1 14
’20 5 6 6 8 25
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 2 14 — — —
’25 11 23 33 13 79
’24 9 9 14 21 54
’23 0 6 15 10 31
’22 (6) (3) (16) 36 11
’21 2 5 3 0 9
’20 4 5 5 7 21
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

2
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Ten-year view Analyst estimates Powerpack
Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 TTM Sep ’26 Trend 10 yrs 2026e 2027e 2028e Next 3/yr
Income, $m
Income, $m Revenue 146 148 190 198 179 206 354 400 504 603 650 +17.1% 658 699 749 +7.5%
Gross margin, % 23.71 24.00 25.36 27.20 24.91 24.77 25.51 28.05 29.08 28.27 28.95 +4.6 pt
EBT 12 12 18 24 16 21 53 54 73 83 94 +23.5%
EBT margin, % 8.43 8.02 9.66 11.92 9.08 10.28 14.90 13.47 14.48 13.69 14.43 +5.3 pt
Net income 8 9 14 20 13 16 42 45 59 68 72 +27.0%
Per share, $
Per share, $ Revenue 20.32 20.40 25.92 26.72 23.97 27.42 46.77 52.48 65.78 78.23 83.85 +16.2%
Earnings 1.11 1.27 1.95 2.66 1.79 2.11 5.52 5.89 7.69 8.87 9.90 +26.0%
Cash flow 1.29 2.41 2.90 4.21 3.35 1.90 2.35 5.42 8.68 11.93 0.00 +28.0%
Capex (1.00) (1.43) (0.73) (0.78) (0.57) (0.70) (0.93) (1.38) (1.68) (1.67) 0.00 +5.9%
Free cash flow 0.29 0.98 2.17 3.43 2.78 1.20 1.41 4.05 7.01 10.26 0.00 +48.4%
Book value 15.72 17.07 19.12 21.82 23.64 25.84 31.40 37.53 44.70 55.01 62.71 +14.9%
Shares, m 7 7 7 7 7 8 8 8 8 8 8 +0.8%
Valuation, ×
Valuation, × P/E 23.20 21.87 15.48 18.65 26.03 33.30 20.94 28.16 31.80 25.03 30.06 24.4
P/S 1.27 1.35 1.16 1.86 1.94 2.56 2.47 3.16 3.72 2.84 3.55 2.2
P/B 1.64 1.61 1.57 2.27 1.97 2.72 3.68 4.42 5.47 4.04 4.99 2.9
EV/Sales 1.06 1.09 1.27 1.85 1.82 2.91 2.61 3.23 4.09 3.05 3.67 2.3
EV/FCF 73.19 22.82 15.19 14.44 15.68 66.54 86.58 41.86 38.39 23.28 38.72 39.8
Cash, $m
Cash, $m Operating cash flow 9 17 21 31 25 14 18 41 67 92 72 +29.0%
Capex (7) (10) (5) (6) (4) (5) (7) (10) (13) (13) (10) +6.7%
Free cash flow 2 7 16 25 21 9 11 31 54 79 62 +49.5%
Balance, $m
Balance, $m Working capital 60 65 35 36 57 49 60 86 119 126 153 +8.5%
Net debt (31) (38) 22 (1) (23) 71 51 27 188 129 75 n/m
Shareholders’ equity 113 124 140 162 177 194 238 286 343 424 486 +15.8%
Returns, %
Returns, % ROA 6.44 6.92 8.73 10.44 6.82 5.91 11.73 11.48 11.42 10.64 11.46 +4.2 pt
ROIC 9.26 8.52 7.55 9.57 6.79 5.00 12.02 11.52 9.52 10.44 11.20 +1.2 pt
ROE 7.36 7.78 10.83 13.06 7.89 8.56 19.35 17.16 18.76 17.82 0.00 +10.5 pt
People
People Employees 805 796 1,051 1,154 1,010 2,015 2,968 3,293 4,335 5,349 — +23.4%
Revenue/emp, $m 0.18 0.19 0.18 0.17 0.18 0.10 0.12 0.12 0.12 0.11 — (5.2%)
Negative figures in brackets.
estimates

All 10 years →

Fiscal years to Dec 2025 · latest quarter Sep 2026 · fundamentals updated 5 Nov 2026

UFP Technologies, Inc. vs peers in Medical Devices (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
AXGN AxoGen, Inc. $2.9B — (loss-making) — (loss-making) +26.22% (above 0%: growing) +163.16% (above 0%: growing) +994.99% (above 0%: growing) 74.81% 1.26% Compare
NEOG Neogen Corporation $2.6B — (loss-making) — (loss-making) +6.50% (above 0%: growing) n/m +135.61% (above 0%: growing) 47.35% (0.81%) Compare
TMDX TransMedics Group, Inc. $2.4B 16.4× 49.4× +41.15% (above 0%: growing) −30.99% (below 0%: shrinking) −55.44% (below 0%: shrinking) 58.45% 13.86% Compare
UFPT UFP Technologies, Inc. $2.3B 30.1× 29.2× +11.57% (above 0%: growing) +25.55% (above 0%: growing) −35.77% (below 0%: shrinking) 29.44% 16.01%
INSP Inspire Medical Systems, Inc. $1.9B 19.1× — (loss-making) −7.93% (below 0%: shrinking) n/m −33.06% (below 0%: shrinking) 86.05% (13.89%) Compare
ESTA Establishment Labs Holdings Inc. $1.9B — (loss-making) — (loss-making) +31.66% (above 0%: growing) n/m +2.75% (above 0%: growing) 70.64% (6.35%) Compare
ALMR Alamar Biosciences, Inc. $1.9B — (loss-making) — (loss-making) +156.24% (above 0%: growing) n/m −20.26% (below 0%: shrinking) 61.54% (45.13%) Compare
BFLY Butterfly Network, Inc. $1.6B — (loss-making) — (loss-making) +51.70% (above 0%: growing) n/m +12.61% (above 0%: growing) 73.02% (41.66%) Compare
NVCR NovoCure Limited $1.6B — (loss-making) — (loss-making) +15.67% (above 0%: growing) n/m +5.54% (above 0%: growing) 76.98% (3.19%) Compare
Median of peers $1.9B — — +28.94% — +4.15% 71.83% (4.77%)

All 149 Medical Devices stocks →

Pay and ownership Proxy statement filed 30 April 2026

Chief executive’s pay

Year Total pay Actually paid $100 invested
2025 7.65m 8.17m 476.22
2024 5.28m 9.48m 524.50
2023 4.93m 8.41m 369.09
2022 4.30m 6.62m 252.95
2021 2.62m 4.14m 150.77

Ownership

Directors and executive officers, together 4.59%
Blackrock, Inc 14.19%
Wasatch Advisors LP 10.12%
Vanguard Group, Inc. 6.90%
Congress Asset Management Co. 5.70%
Total pay is as the Summary Compensation Table states it; actually paid revalues the year’s share awards at its end, as the SEC’s pay-versus-performance rule asks. $100 invested is what $100 in the company’s shares at the start of the earliest year shown was worth at each year’s end. Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more. Read the proxy statement

UFP Technologies, Inc. (UFPT) Latest News

4 Nov

Impact 3 · · The Motley Fool
Impact 3 · · MarketBeat transcript
Impact 3 · · GuruFocus.com
Impact 3 · · The Motley Fool transcript
Impact 3 · · Moby

3 Nov

Impact 3 · · StockStory
Impact 3 · · Associated Press
Impact 3 · · Business Wire

29 Oct

Impact 3 · · Business Wire

22 Oct

Impact 3 · · StockStory

6 Oct

Impact 3 · · StockStory

26 Sep

Impact 3 · · Simply Wall St.

25 Sep

Impact 3 ·

3 Sep

Impact 4 ·

28 Aug

Impact 4 · · MarketBeat

10 Aug

Impact 3 · · The Motley Fool transcript

4 Aug

Impact 4 ·
Impact 4 · · The Motley Fool
Impact 3 · · MarketBeat
Impact 3 · · Moby transcript

3 Aug

Impact 4 ·
Impact 4 ·
Impact 3 ·

2 Aug

Impact 3 ·

13 May

Impact 4 · · Simply Wall St.
Impact 3 · · StockStory

6 May

Impact 3 ·

5 May

Impact 4 · · MarketBeat
Impact 4 · · Moby
Impact 4 · · Simply Wall St.

UFPT metrics, ten years each

stockrow.com/UFPT · Data as of Nov 5, 2026 · For information only; not investment advice. · © 2026 stockrow.com